Stoke Therapeutics (STOK) EBIT Margin: 2022-2025
Historic EBIT Margin for Stoke Therapeutics (STOK) over the last 4 years, with Sep 2025 value amounting to -405.30%.
- Stoke Therapeutics' EBIT Margin rose 20776.00% to -405.30% in Q3 2025 from the same period last year, while for Sep 2025 it was 13.23%, marking a year-over-year increase of 71383.00%. This contributed to the annual value of -277.31% for FY2024, which is 102990.00% up from last year.
- According to the latest figures from Q3 2025, Stoke Therapeutics' EBIT Margin is -405.30%, which was down 105.13% from -197.58% recorded in Q2 2025.
- In the past 5 years, Stoke Therapeutics' EBIT Margin registered a high of 70.15% during Q1 2025, and its lowest value of -1,340.67% during Q2 2023.
- Over the past 3 years, Stoke Therapeutics' median EBIT Margin value was -607.37% (recorded in 2024), while the average stood at -562.32%.
- In the last 5 years, Stoke Therapeutics' EBIT Margin tumbled by 55,955bps in 2023 and then soared by 99,551bps in 2024.
- Stoke Therapeutics' EBIT Margin (Quarterly) stood at -831.58% in 2022, then plummeted by 22,431bps to -1,055.89% in 2023, then spiked by 99,551bps to -60.37% in 2024, then skyrocketed by 20,776bps to -405.30% in 2025.
- Its last three reported values are -405.30% in Q3 2025, -197.58% for Q2 2025, and 70.15% during Q1 2025.